Page last updated: 2024-11-05

etozolin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

etozolin: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6304
CHEBI ID135174
MeSH IDM0064307

Synonyms (8)

Synonym
ethyl (3-methyl-4-oxo-5-piperidinothiazolidin-2-ylidene)acetate
etozoline
etozolin
73-09-6
CHEBI:135174
ethyl-3-methyl-4-oxo-5-piperidino-2-thiazolidinylidenacetat
DTXSID40874489
(+/-)-etozolin; (+/-)-etozoline;go 787; nsc 310039; w 2900a

Research Excerpts

Overview

Etozolin is a new diuretic with hypotensive properties.

ExcerptReferenceRelevance
"Etozolin is a new diuretic with hypotensive properties. "( [Etozolin and captopril in the treatment of arterial hypertension].
Adamo, M; Battaglia, A; Di Stefano, G; Gargano, F, 1990
)
2.63

Treatment

ExcerptReferenceRelevance
"Treatment with etozolin led to a reduction of arterial blood pressure from 187/112 +/- 10/4 mmHg to 167/99 +/- 7/6 mmHg; for captopril the corresponding figures were from 186/112 +/- 11.5 mmHg to 163/98 +/- 7.4 mmHg and for the combination from 188/112 +/- 10/5 mmHg to 154/86 +/- 6/5 mmHg."( [Etozolin and captopril in the treatment of arterial hypertension].
Adamo, M; Battaglia, A; Di Stefano, G; Gargano, F, 1990
)
1.53

Compound-Compound Interactions

ExcerptReferenceRelevance
" The combination with verapamil may be effective in those who do not respond to etozolin alone."( Etozolin monotherapy and combination with verapamil in essential hypertension.
Agabiti-Rosei, E; Muiesan, G, 1989
)
1.95

Dosage Studied

ExcerptRelevanceReference
" It is concluded that these changes in the kinetics of this lipophilic diuretic do not allow a reliable dosage regimen in patients with hepatic cirrhosis and ascites."( Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
Gerok, W; Knauf, H; Missmahl, M; Mutschler, E; Schölmerich, J, 1987
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (77.27)18.7374
1990's3 (13.64)18.2507
2000's0 (0.00)29.6817
2010's2 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.26 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (18.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (27.59%)5.53%
Reviews2 (6.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (65.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]